BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.

Exosomes transform prostate cancer care with early detection, tailored treatments, and real-time prognosis tracking for ...

One year after becoming the first centre to open a global clinical trial of a radioligand therapy for metastatic prostate ...

Genetic testing for hereditary cancer unexpectedly uncovered a case of myelodysplastic syndrome (MDS), highlighting the need ...

A new study employing novel single-cell multimodal data revealed key insights into the tumor microenvironment predictive of NSCLC treatment response.

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

As the authors reported in Radiology Case Reports, the patient had no history of cancer and had no pain, weakness, numbness, or other spine-related symptoms. Lab tests confirmed she had severe anemia; ...

A rogue protein just yanked the plug on cancer’s energy grid. And researchers at the Duke University School of Medicine just figured out how. In a new study led by cancer researcher Hui-Kuan Lin, PhD, ...

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...